IFP Advisors Inc Has $7.42 Million Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

IFP Advisors Inc boosted its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 5.3% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 188,062 shares of the biopharmaceutical company's stock after acquiring an additional 9,515 shares during the quarter. IFP Advisors Inc owned 0.12% of TG Therapeutics worth $7,415,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of TGTX. Vanguard Group Inc. lifted its holdings in shares of TG Therapeutics by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 15,596,480 shares of the biopharmaceutical company's stock valued at $469,454,000 after buying an additional 209,190 shares during the last quarter. Soleus Capital Management L.P. lifted its holdings in TG Therapeutics by 5.8% in the 4th quarter. Soleus Capital Management L.P. now owns 2,681,242 shares of the biopharmaceutical company's stock worth $80,705,000 after purchasing an additional 146,702 shares during the last quarter. Clearbridge Investments LLC acquired a new stake in TG Therapeutics in the 4th quarter worth approximately $55,237,000. Northern Trust Corp lifted its holdings in TG Therapeutics by 8.6% in the 4th quarter. Northern Trust Corp now owns 1,532,929 shares of the biopharmaceutical company's stock worth $46,141,000 after purchasing an additional 120,785 shares during the last quarter. Finally, Invesco Ltd. lifted its holdings in TG Therapeutics by 1.2% in the 4th quarter. Invesco Ltd. now owns 929,743 shares of the biopharmaceutical company's stock worth $27,985,000 after purchasing an additional 10,989 shares during the last quarter. 58.58% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Yann Echelard sold 10,000 shares of the company's stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $36.94, for a total value of $369,400.00. Following the completion of the sale, the director owned 228,816 shares in the company, valued at approximately $8,452,463.04. This represents a 4.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 10.64% of the company's stock.

Analysts Set New Price Targets

Separately, The Goldman Sachs Group raised TG Therapeutics to a "hold" rating and set a $37.00 price target on the stock in a research report on Thursday, July 10th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $43.80.

TG Therapeutics Price Performance

TG Therapeutics stock opened at $37.91 on Friday. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.04 and a current ratio of 4.02. The firm has a market cap of $6.02 billion, a P/E ratio of 157.96 and a beta of 1.91. The business's fifty day moving average is $36.41 and its two-hundred day moving average is $35.55. TG Therapeutics, Inc. has a 52 week low of $16.65 and a 52 week high of $46.48.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.16). TG Therapeutics had a net margin of 10.13% and a return on equity of 18.88%. The firm had revenue of $120.86 million for the quarter, compared to analyst estimates of $117.07 million. During the same period last year, the company earned ($0.07) EPS. The company's revenue was up 90.4% compared to the same quarter last year. Equities research analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.